Cooper H A, Reisner F F, Hall M, Wagner R H
J Clin Invest. 1975 Sep;56(3):751-60. doi: 10.1172/JCI108146.
When human, canine, or bovine factor VIII preparations are chromatographed on 4% agarose at ionic strength 0.2, the factor VIII activity elutes as a single peak in the void volume with slight tailing. Incubation of such preparations with dilute (0.01 U/ml) highly purified thrombin results in some activation of factor VIII. Chromatography of such incubation mixtures, under the same conditions as before, results in elution of two peaks of factor VIII activity one in the void volume and one much later with marked tailing. The void volume peak has most of the protein and some factor VIII activity. These void volume fractions also contain all the von Willebrand factor activity of thrombin-treated bovine preparations. Longer treatment with thrombin, or treatment with stronger thrombin, appears to shift much more of the procoagulant activity to the later eluting peak. Also, when the peak of factor VIII activity, found in the void volume after thrombin treatment, was again incubated with dilute thrombin, an increase in factor VIII activity occurred. Chromatography of this incubation mixture demonstrated only a small amount of activity in the void volume, while the bulk of the activity was present in the second peak. On the other hand, thrombin treatment of factor VIII activity from peak 2 caused a rapid decline of activity instead of a further increase. It is proposed that the residual factor VIII activity found in the void volume represents unreacted factor VIII, while the late eluting peak represents thrombin-activated material that is of smaller apparent size. The late eluting peak differs from the small active factor VIII fragment obtained by Ca2+ dissociation, as the latter can be activated by thrombin. A similar set of experiments was performed using ultracentifugation of bovine factor VIII preparations on sucrose density gradients. Results of these experiments agreed completely with those obtained with get chromatography. Preparations made from human hemophilic plasma, by the procudure employed in the purification of human factor VIII, were also incubated with thrombin and chromatographed. von Willebrand factor was again found only in the void volume fractions, but there was no factor VIII activity in any fractions eluted. In other control experiments, activated and unactivated factor VIII fractions did not clot fibrinogen and contained no assayable factor IX or X. The thrombin-modified factor VIII of small size was inactivated by both a naturally occurring human inhibitor to factor VIII and the gamma globulin fraction of a rabbit antisera produced against the calcium-dissociated small active factor VIII fragment.
当将人、犬或牛的凝血因子VIII制剂在离子强度为0.2的4%琼脂糖上进行色谱分析时,凝血因子VIII活性以单一峰的形式在空体积中洗脱,并有轻微拖尾。将此类制剂与稀释的(0.01 U/ml)高度纯化的凝血酶一起孵育会导致凝血因子VIII的一些活化。在与之前相同的条件下对此类孵育混合物进行色谱分析,会导致凝血因子VIII活性出现两个峰的洗脱,一个在空体积中,另一个在很久之后出现且有明显拖尾。空体积峰含有大部分蛋白质和一些凝血因子VIII活性。这些空体积级分还包含凝血酶处理过的牛制剂的所有血管性血友病因子活性。用凝血酶进行更长时间的处理或用更强的凝血酶处理,似乎会使更多的促凝活性转移到较晚洗脱的峰中。此外,当在凝血酶处理后在空体积中发现的凝血因子VIII活性峰再次与稀释的凝血酶一起孵育时,凝血因子VIII活性会增加。对此孵育混合物进行色谱分析表明,空体积中只有少量活性,而大部分活性存在于第二个峰中。另一方面,用凝血酶处理来自峰2的凝血因子VIII活性会导致活性迅速下降,而不是进一步增加。有人提出,在空体积中发现的残留凝血因子VIII活性代表未反应的凝血因子VIII,而较晚洗脱的峰代表表观尺寸较小的凝血酶活化物质。较晚洗脱的峰与通过Ca2+解离获得的小活性凝血因子VIII片段不同,因为后者可被凝血酶活化。使用牛凝血因子VIII制剂在蔗糖密度梯度上进行超速离心进行了一组类似的实验。这些实验的结果与凝胶色谱法获得的结果完全一致。用人血友病血浆通过纯化人凝血因子VIII所采用的方法制备的制剂也与凝血酶一起孵育并进行色谱分析。再次仅在空体积级分中发现血管性血友病因子,但在任何洗脱级分中均无凝血因子VIII活性。在其他对照实验中,活化和未活化的凝血因子VIII级分均不能使纤维蛋白原凝固,且不含可检测的凝血因子IX或X。小尺寸的凝血酶修饰的凝血因子VIII被天然存在的人凝血因子VIII抑制剂和针对钙解离的小活性凝血因子VIII片段产生的兔抗血清的γ球蛋白级分所灭活。